Shuqun Lin

This inventor holds 15 USPTO granted patents and 2 published patent applications and 8 EPO patents, primarily in Heterocyclic Compounds. Top assignee: Bristol-Myers Squibb Compnay. Active years: 2008-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shuqun Lin. Retrieved from https://idiyas.com/inventor/shuqun-lin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 15 (Patent Applications = 2)

% Patents Active = 100.0

EPO Patents = 8 (Patent Applications = 7)

Average Co-Inventor Count = 6.8

ph-index = 5

Forward Citations = 110(Granted Patents)

Location History:

Newtown, NJ (US) (2019)
Newtown, PA (US) (2008 - 2020)

Company Filing History:

15 out of 3,749

Bristol-Myers Squibb Compnay

patents

Years Active: 2008-2020

Loading Chart...

Areas of Expertise:

Heterocyclic Compounds

Kinase Inhibitors

JAK3 Inhibitors

IL-12 Modulators

Inflammatory Diseases

Autoimmune Diseases

Amide Compounds

Pyridyl Compounds

Pyrrolopyridazine

Tricyclic Compounds

Phenyl-substituted

Fused Compounds

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. RE47929 - Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses (2020-04-06),

2. 10526321 - Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses (2020-01-07),

3. 10308652 - Tricyclic heterocyclic compounds useful as inhibitors of TNF (2019-06-04),

4. 10000480 - Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses (2018-06-19),

5. 9505748 - Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses (2016-11-29),

6. 9315494 - Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responses (2016-04-19),

7. 9221826 - Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases (2015-12-29),

8. 8987268 - Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases (2015-03-24),

9. 8921368 - Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases (2014-12-30),

10. 8404689 - Heterocyclic amide compounds useful as kinase inhibitors (2013-03-26),

11. 7935696 - Heterocyclic amide compounds useful as kinase inhibitors (2011-05-03),

12. 7923556 - Phenyl-substituted pyrimidine compounds useful as kinase inhibitors (2011-04-12),

13. 7723336 - Fused heterocyclic compounds useful as kinase modulators (2010-05-25),

14. 7642257 - Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors (2010-01-05),

15. 7419978 - Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors (2008-09-02),

Title: Innovations of Shuqun Lin in Modulating Immune Responses

Introduction

Shuqun Lin is a prominent inventor based in Newtown, PA, known for his significant contributions to the field of pharmaceutical sciences. With a total of 15 patents to his name, Lin has focused on developing compounds that modulate immune responses, particularly in relation to IL-12, IL-23, and IFN alpha.

Latest Patents

Among his latest patents are the amide-substituted heterocyclic compounds that serve as modulators of IL-12, IL-23, and/or IFN alpha responses. These compounds are characterized by a specific formula and include stereoisomers or pharmaceutically acceptable salts. They are designed to act on Tyk-2, leading to signal transduction inhibition, which is crucial for therapeutic applications in immune modulation.

Career Highlights

Shuqun Lin is currently associated with Bristol-Myers Squibb Company, where he continues to innovate and develop new pharmaceutical solutions. His work has been instrumental in advancing the understanding of immune modulation and its applications in treating various diseases.

Collaborations

Lin has collaborated with notable colleagues such as Stephen T. Wrobleski and John S. Tokarski, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Shuqun Lin's work exemplifies the intersection of scientific research and practical application in the pharmaceutical industry. His innovative patents and collaborations highlight his commitment to advancing medical science and improving patient outcomes.

Profile summary based on public USPTO records.